Basilea Pharmaceutica (FRA:PK5) Beta: 0.1064 (As of Jun. 27, 2026)


FRA:PK5 Basilea Pharmaceutica Ltd FRA:PK5
62 GF Score
Price €56.30
GF Value €60.85
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Basilea Pharmaceutica Beta?

Basilea Pharmaceutica FRA:PK5 +0.90% 62 Beta is 0.1064 as of Jun. 27, 2026. GuruFocus rates FRA:PK5 with a GF Score™ of 62/100 and a GF Value™ of €60.85 (Fairly Valued). The stock has 2 warning signs investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-06-27), Basilea Pharmaceutica's Beta is 0.1064.


Basilea Pharmaceutica  (FRA:PK5) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Basilea Pharmaceutica Beta Related Terms


Basilea Pharmaceutica Beta Historical Data

* Premium members only.

The historical data trend for Basilea Pharmaceutica's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Basilea Pharmaceutica Beta Chart

Basilea Pharmaceutica Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.22 0.00 0.00 0.00 0.02

Basilea Pharmaceutica Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.10 0.02

FRA:PK5 vs VRTX, REGN, ALNY: Beta Comparison

For the Biotechnology subindustry, Basilea Pharmaceutica's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Basilea Pharmaceutica Beta vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Basilea Pharmaceutica's Beta distribution charts can be found below:

* The bar in red indicates where Basilea Pharmaceutica's Beta falls into.


FRA:PK5
62GF Score
Basilea Pharmaceutica Ltd FRA:PK5
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Basilea Pharmaceutica Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.1064 mean?
Basilea Pharmaceutica (FRA:PK5) has a Beta of 0.1064 as of Jun. 27, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Basilea Pharmaceutica and its competitors.
Is Basilea Pharmaceutica's Beta too high?
Basilea Pharmaceutica's current Beta is 0.1064. Overall, Basilea Pharmaceutica has a GF Score™ of 62/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Basilea Pharmaceutica's Beta compare to VRTX and REGN?
Basilea Pharmaceutica's Beta of 0.1064 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Biotechnology company?
A good Beta depends on the Biotechnology industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Basilea Pharmaceutica and its competitors. Basilea Pharmaceutica's current Beta is 0.1064. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Basilea Pharmaceutica stock overvalued right now?
Based on GuruFocus' analysis, Basilea Pharmaceutica (FRA:PK5) is currently considered Fairly Valued. The stock's GF Value™ is €60.85, compared to a current price of €56.30 — trading 7.5% below its estimated fair value. The current Beta is 0.1064. Basilea Pharmaceutica's overall GF Score™ is 62/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Basilea Pharmaceutica (FRA:PK5), the current Beta is 0.1064 as of Jun. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Basilea Pharmaceutica (FRA:PK5) Overvalued in 2026?

Based on GuruFocus' analysis, Basilea Pharmaceutica stock appears to be undervalued. The current stock price of €56.30 is trading 7.5% below its estimated GF Value™ of €60.85. GuruFocus considers Basilea Pharmaceutica to be Fairly Valued.

Key valuation signals for FRA:PK5:

  • Beta: 0.1064
  • GF Value™: €60.85 vs. price of €56.30 (7.5% below fair value)
  • GF Score™: 62/100 with 2 warning signs

No single metric tells the full story. See the FRA:PK5 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Basilea Pharmaceutica Business Description

Address Hegenheimermattweg 167b, Allschwil, CHE, 4123
Basilea Pharmaceutica Ltd is a commercial-stage biopharmaceutical company committed to discovering, developing and commercializing drugs to meet the needs of patients with severe bacterial and fungal infections. The Company has operating subsidiaries in the United Kingdom and Germany. Geographically company derives revenue from Japan, Ireland, Republic of Korea, USA, Uruguay, Sweden, Canada, Jordan, Switzerland and Other countries.
62GF Score

Get the complete analysis for FRA:PK5

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€56.30
Price
€60.85
GF Value